'Toxgnostics': an unmet need in cancer medicine

被引：20

作者：

Church, David ^{[1
,2
]}

Kerr, Rachel ^{[1
]}

Domingo, Enric ^{[2
]}

Rosmarin, Dan ^{[2
]}

Palles, Claire ^{[2
]}

Maskell, Kevin ^{[4
]}

Tomlinson, Ian ^{[2
,3
]}

Kerr, David ^{[5
]}

机构：

[1] Univ Oxford, Churchill Hosp, Dept Oncol, Oxford Canc Ctr, Oxford OX3 7LE, England

[2] Univ Oxford, Wellcome Trust Ctr Human Genet, Mol & Populat Genet Lab, Oxford OX3 7BN, England

[3] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford Comprehens Biomed Res Ctr, Oxford OX3 7BN, England

[4] Magdalen Ctr, Oxford OX4 4GA, England

[5] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England

来源：

NATURE REVIEWS CANCER | 2014年 / 14卷 / 06期

基金：

英国惠康基金;

关键词：

METASTATIC COLORECTAL-CANCER; GENOME-WIDE ASSOCIATION; DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY; HER2-POSITIVE BREAST-CANCER; III COLON-CANCER; GROUP; 1-98; TRIAL; ADJUVANT CHEMOTHERAPY; GENETIC-VARIANTS; POSTMENOPAUSAL WOMEN; FEBRILE NEUTROPENIA;

D O I：

10.1038/nrc3729

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

If we were to summarize the rationale that underpins medical oncology in a Latin aphorism, it might be 'veneno ergo sum'; that is, I poison, therefore I am. The burden of chemotherapy-associated toxicity is well recognized, but we have relatively few tools that increase the precision of anticancer drug prescribing. We propose a shift in emphasis from the focussed study of polymorphisms in drug metabolic pathways in small sets of patients to broader agnostic analyses to systematically correlate germline genetic variants with adverse events in large, well-defined cancer populations. Thus, we propose the new science of 'toxgnostics' (that is, the systematic, agnostic study of genetic predictors of toxicity from anticancer therapy).

引用

收藏

页码：440 / 445

页数：6

相关论文

共 95 条

[1]

Ahmed G., 2013, J CLIN ONCOL S, V31

[2]

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[3]

UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan [J].

Ando, Y ;

Saka, H ;

Asai, G ;

Sugiura, S ;

Shimokata, K ;

Kamataki, T .

ANNALS OF ONCOLOGY, 1998, 9 (08) :845-847

[4]

A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101 [J].

Baldwin, R. Michael ;

Owzar, Kouros ;

Zembutsu, Hitoshi ;

Chhibber, Apama ;

Kubo, Michiaki ;

Jiang, Chen ;

Watson, Dorothy ;

Eclov, Rachel J. ;

Mefford, Joel ;

McLeod, Howard L. ;

Friedman, Paula N. ;

Hudis, Clifford A. ;

Winer, Eric P. ;

Jorgenson, Eric M. ;

Witte, John S. ;

Shulman, Lawrence N. ;

Nakamura, Yusuke ;

Ratain, Mark J. ;

Kroetz, Deanna L. .

CLINICAL CANCER RESEARCH, 2012, 18 (18) :5099-5109

[5]

Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer-A Study of CALGB 9581 and 89803 [J].

Bertagnolli, Monica M. ;

Redston, Mark ;

Compton, Carolyn C. ;

Niedzwiecki, Donna ;

Mayer, Robert J. ;

Goldberg, Richard M. ;

Colacchio, Thomas A. ;

Saltz, Leonard B. ;

Warren, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (23) :3153-3162

[6]

Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia [J].

Blay, JY ;

Chauvin, F ;

LeCesne, A ;

Anglaret, B ;

Bouhour, D ;

Lasset, C ;

Freyer, G ;

Philip, T ;

Biron, P .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) :636-643

[7]

Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting [J].

Burmeister, Henning ;

Aebi, Stefan ;

Studer, Cristina ;

Fey, Martin F. ;

Gautschi, Oliver .

SUPPORTIVE CARE IN CANCER, 2012, 20 (01) :141-147

[8]

Biomarkers and surrogate end points-the challenge of statistical validation [J].

Buyse, Marc ;

Sargent, Daniel J. ;

Grothey, Axel ;

Matheson, Alastair ;

De Gramont, Aimery .

NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (06) :309-317

[9]

Evaluating the total costs of chemotherapy-induced toxicity: Results from a pilot study with ovarian cancer patients [J].

Calhoun, EA ;

Chang, CH ;

Welshman, EE ;

Fishman, DA ;

Lurain, JR ;

Bennett, CL .

ONCOLOGIST, 2001, 6 (05) :441-445

[10]

CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].

CALVERT, AH ;

NEWELL, DR ;

GUMBRELL, LA ;

OREILLY, S ;

BURNELL, M ;

BOXALL, FE ;

SIDDIK, ZH ;

JUDSON, IR ;

GORE, ME ;

WILTSHAW, E .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756

← 1 2 3 4 5 6 7 8 9 10 →